Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrc3925 http://scihub22266oqcxt.onion/10.1038/nrc3925 C4798425!4798425 !25998714     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25998714 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Nat+Rev+Cancer 2015 ; 15 (6 ): 347-60 Nephropedia Template TP {{tp|p=25998714 |t=2015. Radioimmunotherapy of human tumours |pdf=|usr=}}{{25998714 }} gab.com Text Radioimmunotherapy of human tumours JO: Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=25998714 #FOAvip The eradication of cancer remains a vexing problem despite recent advances in our understanding of the molecular basis of neoplasia. One therapeutic approach that has demonstrated potential involves the selective targeting of radionuclides to cancer-associated cell surface antigens using monoclonal antibodies. Such radioimmunotherapy (RIT) permits the delivery of a high dose of therapeutic radiation to cancer cells, while minimizing the exposure of normal cells. Although this approach has been investigated for several decades, the cumulative advances in cancer biology, antibody engineering and radiochemistry in the past decade have markedly enhanced the ability of RIT to produce durable remissions of multiple cancer types. Twit Text FOAVip Radioimmunotherapy of human tumours ????Nat Rev Cancer http://www.kidney.de/pget.php?&tw=1&pmid=25998714 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25998714 #FOAvip English Wikipedia <ref>{{Cite pmid|25998714 }}</ref> Radioimmunotherapy of human tumours #MMPMID25998714 Larson SM ; Carrasquillo JA ; Cheung NK ; Press OW Nat Rev Cancer 2015[Jun]; 15 (6 ): 347-60 PMID25998714 show ga The eradication of cancer remains a vexing problem despite recent advances in our understanding of the molecular basis of neoplasia. One therapeutic approach that has demonstrated potential involves the selective targeting of radionuclides to cancer-associated cell surface antigens using monoclonal antibodies. Such radioimmunotherapy (RIT) permits the delivery of a high dose of therapeutic radiation to cancer cells, while minimizing the exposure of normal cells. Although this approach has been investigated for several decades, the cumulative advances in cancer biology, antibody engineering and radiochemistry in the past decade have markedly enhanced the ability of RIT to produce durable remissions of multiple cancer types. |Actinium/administration & dosage/therapeutic use [MESH] |Alpha Particles/therapeutic use [MESH] |Antibodies, Monoclonal/administration & dosage/pharmacology [MESH] |Clinical Trials as Topic [MESH] |Hematologic Neoplasms/radiotherapy [MESH] |Humans [MESH] |Molecular Targeted Therapy/methods [MESH] |Neoplasms/*radiotherapy [MESH]Radioimmunotherapy of human tumours (epmc).pdf DeepDyve Pubget Overpricing